21羟化酶缺陷年轻成人糖皮质激素替代治疗下骨健康正常
这项病例对照研究比较了23例21羟化酶缺陷所致先天性肾上腺增生症年轻患者与20名年龄匹配对照者的骨密度和骨状态,发现患者整体骨健康正常,仅股骨颈骨密度与糖皮质激素剂量独立相关。
要点
- 21羟化酶缺陷年轻成人接受糖皮质激素替代治疗时骨密度和骨状态与对照无差异。
- 相对骨骼肌指数独立正相关于全身、腰椎和股骨颈骨密度。
- 糖皮质激素剂量仅独立负相关于股骨颈骨密度。
核心结论
- 21羟化酶缺陷年轻成人接受糖皮质激素替代治疗时未观察到骨健康改变。
- 肌肉减少症标志物在所有分析骨骼部位均与骨密度相关。
- 仅股骨颈骨密度显著依赖糖皮质激素剂量。
研究设计与样本
- 病例对照研究纳入23例21羟化酶缺陷患者(7男16女)和20名年龄范围18至31岁匹配的对照(8男12女)。
- 采用双能X线吸收法和指骨定量超声分别评估骨密度和骨状态。
主要发现
- 患者与对照(两性)在全身、腰椎和股骨颈骨密度绝对值及Z值上无差异。
- 指骨定量超声评估的骨状态在患者与对照间无差异。
- 多元线性回归显示相对骨骼肌指数独立相关于全身骨密度(β:0.67,P=0.007)、腰椎骨密度(β:0.73,P=0.005)和股骨颈骨密度(β:0.67,P=0.007)。
- 糖皮质激素剂量独立相关于股骨颈骨密度(β:-0.38,P=0.028)。
临床怎么用
- 对于21羟化酶缺陷接受糖皮质激素替代治疗的年轻成人,应关注股骨颈骨密度并优化糖皮质激素剂量。
- 评估骨骼肌指数可能有助于识别骨密度降低风险。
局限性
- 样本量较小(患者23例,对照20例)。
- 为病例对照设计,无法确定因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: It is of great importance to investigate any potential detrimental effect on bone health in young adults with 21-hydroxylase enzyme deficiency undergoing glucocorticoid replacement therapy. This study demonstrated normal bone health in well-controlled patients. Additionally, glucocorticoid dose may play an important role in the mineral density of femoral neck region. PURPOSE: To compare regional bone mineral densities (BMDs) and bone statuses of young adults with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase enzyme (21OHase) deficiency with a control group. The duration and dose of glucocorticoid therapy and relative skeletal muscle index (an indicator of sarcopenia) were also analyzed as parameters to predict bone health. METHODS: This case-control study included 23 patients (7 male and 16 female) and 20 controls (8 male and 12 female) matched by age range (18 to 31 years). Dual energy X-ray absorptiometry and phalangeal quantitative ultrasound (QUS) were used to estimate BMD and bone status, respectively. RESULTS: No difference was observed between patients and controls (of both sexes) in absolute values of BMD and Z-scores for the total body, lumbar spine, and femoral neck; or the bone status (estimated by phalangeal QUS). Multiple linear regression analysis demonstrated that relative skeletal muscle index independently correlated with BMD of the entire body (β: 0.67, P = 0.007), the lumbar spine (β: 0.73, P = 0.005), and the femoral neck (β: 0.67, P = 0.007). However, the dose of glucocorticoids (β: - 0.38, P = 0.028) independently correlated with BMD in the femoral neck region alone. CONCLUSION: No signs of change in bone health were observed in patients with CAH when compared to the reference group. Additionally, a marker of sarcopenia was demonstrated to have a role in mineral density mechanisms in all analyzed bone sites. Only the femoral neck BMD seemed to be significantly dependent on glucocorticoid dose.
引用
- Borges JH, de Oliveira DM, de Lemos-Marini SHV, et al. Normal bone health in young adults with 21-hydroxylase enzyme deficiency undergoing glucocorticoid replacement therapy. Osteoporos Int. 2021. PMID: 34406442. doi:10.1007/s00198-021-06097-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。